GLP-1受体激动剂与男性性功能:心血管代谢获益如何转化为勃起功能结果
Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes
Noakes等人指出,GLP-1受体激动剂对勃起功能的有益效果主要源于减重等间接心血管代谢改善,直接血管或激素影响证据有限。尽管exenatide和semaglutide观察性研究报告了性功能障碍关联,但随机试验未证实短期暴露对生殖激素有害。该类药物异质性大,现有基于早期药物的性健康结论可能无法代表新型制剂。
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transitioned from glucose-lowering therapies for patients with refractory diabetes to a staple in weight management, with increasing use among younger and more metabolically diverse populations. In this context, Noakes et al. provide a timely scoping review examining the relationship between GLP-1 RAs and male sexual function [1]. Their synthesis highlights the conflict commonly encountered in clinical practice: the expectation that metabolic improvement from GLP-1 RAs should benefit erectile function, contrasted with observations that some men report sexual dysfunction while taking these medications.
The central theme of the review is the well-established relationship between cardiometabolic health and erectile function. Obesity, insulin resistance, and systemic inflammation contribute to endothelial dysfunction and impaired penile hemodynamics, and interventions targeting these processes, specifically weight loss, have consistently demonstrated improvements in erectile function. In this context, the beneficial effects on erectile function are most plausibly indirect based on the current literature [2,3]. The contrary evidence for a direct, and weight-independent, vascular or penile hemodynamic effect of GLP-1 RAs remains limited [4]. Similarly, increases in testosterone with GLP-1 RA therapy are best interpreted within the context of decreasing adiposity. As Noakes et al. discussed, in obese men with hypogonadism, weight loss is known to reverse suppression of the hypothalamic-pituitary-gonadal axis, and small studies suggest that GLP-1-mediated weight reduction may lead to increases in testosterone in this population [5,6]. However, there is no evidence to support a direct effect of GLP-1 receptor activation on this effect in eugonadal men. These distinctions are important when counseling patients on the expected effect of this medication class on erectile dysfunction and symptoms associated with hypogonadism, especially when you do not anticipate a dramatic change in weight.
In contrast to these largely favorable physiologic considerations, recent observational TriNetX and safety monitoring studies have reported an association of GLP-1 RA use with sexual dysfunction [7,8]. These adverse effects were most commonly seen in men using exenatide but were also seen with contemporary GLP-1 RA such as semaglutide [8]. These findings warrant attention but should be interpreted cautiously. These analyses are inherently limited by residual confounding variables, including variability in healthcare utilization and non-standardized reporting of sexual symptoms. Moreover, randomized data in healthy men have not demonstrated adverse effects on reproductive hormones or libido with short-term exposure [9]. These observations should not be viewed as definitive evidence of harm but do warrant further investigation.
A recurring limitation in the current literature not discussed in this review is the heterogeneity within the GLP-1 RA class of medications. Many frequently cited studies regarding sexual function outcomes are based on earlier-generation GLP-1 RAs such as exenatide or liraglutide. These medications differ substantially from more recent therapies in their pharmacokinetics, receptor activity, and, importantly, the magnitude of weight loss achieved. Contemporary agents such as semaglutide produce more sustained receptor activation and have demonstrated significantly greater reductions in body weight [10]. The introduction of dual agonists such as tirzepatide and triple agents such as retatrutide further clouds our current assumptions, as they incorporate additional metabolic pathways not captured in the current literature [11,12].
The greater degree of rapid weight loss observed with newer GLP-1 RAs could amplify the beneficial or possibly adverse effects on sexual health previously seen. More pronounced improvements in metabolic health may translate into greater improvement of endothelial function and hormonal balance in some patients. However, rapid weight loss and nutritional deficits could influence libido, energy levels, or sexual performance. Moreover, loss of muscle mass, as has been reported with GLP-1 RA use [13], may also increase the risk of sexual dysfunction [14]. As such, historical findings from earlier, less potent therapies may not fully capture the physiologic and clinical effects of the contemporary regimens. While this evolving class of medications has the potential for dramatic improvement in several health domains, including sexual health and erectile function, observational signals underscore the importance of continued vigilance. As GLP-1 RAs are prescribed for broader indications and with increased potency, we should expect corresponding changes in the magnitude and variability of sexual health outcomes.
References
Noakes J, Daffner M, Burns JT, Bishop AK, Valerio T, Biondi L, et al. GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes. Int J Impot Res. 2026. https://doi.org/10.1038/s41443-026-01254-3.
Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978. https://doi.org/10.1001/jama.291.24.2978.
Li H, Xu W, Wang T, Wang S, Liu J, Jiang H. Effect of weight loss on erectile function in men with overweight or obesity: a meta-analysis of randomised controlled trials. Andrologia. 2022. https://doi.org/10.1111/and.14250.
Koska J, Sands M, Burciu C, D’Souza KM, Raravikar K, Liu J, et al. Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes. 2015;64:2624–35. https://doi.org/10.2337/db14-0976.
Grossmann M. Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol. 2018;89:11–21. https://doi.org/10.1111/cen.13723.
Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8:195–202. https://doi.org/10.1530/EC-18-0514.
Able C, Liao B, Saffati G, Maremanda A, Applewhite J, Nasrallah AA, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Int J Impot Res. 2025;37:315–9. https://doi.org/10.1038/s41443-024-00895-6.
Pourabhari Langroudi A, Chen AL, Basran S, Sommer ER, Stinson J, Cheng YS, et al. Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. Int J Impot Res. 2025;37:661–7. https://doi.org/10.1038/s41443-025-01061-2.
Lengsfeld S, Probst L, Emara Y, Werlen L, Vogt DR, Bathelt C, et al. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine. 2024;107:105284. https://doi.org/10.1016/j.ebiom.2024.105284.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16. https://doi.org/10.1056/NEJMoa2206038.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389:514–26. https://doi.org/10.1056/NEJMoa2301972.
Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113. https://doi.org/10.1016/j.metabol.2024.156113.
Surmeli DM, Karpuzcu HC, Atmis V, Cosarderelioglu C, Yalcin A, Varli M, et al. Association between sarcopenia and erectile dysfunction in older males. Arch Gerontol Geriatr. 2022;99:104619. https://doi.org/10.1016/j.archger.2021.104619.
Author information
Authors and Affiliations
Department of Urology, School of Medicine, Stanford University, Stanford, CA, USA
Nicholas Sellke & Michael L. Eisenberg
Authors
- Nicholas Sellke
- Michael L. Eisenberg
Contributions
NS and ME both drafted the comment and provided critical review and editing. ME provided supervision.
Corresponding author
Correspondence to Nicholas Sellke.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sellke, N., Eisenberg, M.L. Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes. Int J Impot Res (2026). https://doi.org/10.1038/s41443-026-01325-5
Received: 14 April 2026
Revised: 11 June 2026
Accepted: 02 July 2026
Published: 19 October 2026
Version of record: 19 October 2026
DOI: https://doi.org/10.1038/s41443-026-01325-5
来源:Nature 健康护理主题 · nature.com